Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on the Use of Splicing Correction as a Prognostic Biomarker ...

On March 18 th Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will be giving an oral presentation in the first session dedicated to OPMD at the 2025 Muscular ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The Galesburg Fire Department (GFD) really came through for people with neuromuscular diseases at the annual Fill the Boot Campaign. The department ranked second in Illinois for dollars collected ...

Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dys ...

Pratteln, Switzerland Friday, February 14, 2025, 15:00 Hrs [IST] ...

The Swiss biopharma company said the deal with the German National Association of Statutory Health Insurance Funds (GKV-SV) ...

A scheduled charity wrestling event in August will bring a famous name from pro wrestling, who's also a former gold medalist, ...

HAYWARD, Calif. - Benitec Biopharma Inc. (NASDAQ: BNTC), a clinical-stage biotechnology company with a market capitalization of $225 million, announced today that it will present interim data from its ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

Santhera Pharmaceuticals, a Swiss specialty pharma focused on rare diseases, has announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the ...